---

Acetazolamide for Acute Mountain Sickness (AMS) - After Symptoms Appear

---

What is Acetazolamide?

• Fishman's Pulmonary Diseases and Disorders, p. 675

---

For Treatment (After Symptoms Appear)

• Goldman-Cecil Medicine, p. 1465

---

Important Hierarchy: Symptom Severity Matters

1. Life-threatening symptoms (high-altitude pulmonary edema / HACE):
   • Immediate descent is the best treatment
   • Supplemental oxygen
   • Portable hyperbaric chamber if needed
   • Acetazolamide is adjunctive here, not first-line
2. Moderate/less severe AMS symptoms:
   • Acetazolamide 250 mg twice daily - appropriate first-line treatment
   • OR dexamethasone 4 mg every 6 hours
3. Mild AMS (e.g., headache only):
   • NSAIDs (ibuprofen, aspirin), acetaminophen are sufficient
   • Acetazolamide is still appropriate but may be more than necessary

• Goldman-Cecil Medicine, pp. 1463-1465

---

Why It Works (Mechanism)

• Bicarbonate wasting in the kidney → mild metabolic acidosis
• The acidosis directly stimulates chemoreceptors → increases respiratory rate and depth
• Better ventilation → improved oxygenation at altitude
• Also may increase cerebral blood flow independently

---

Side Effects to Know

• Peripheral tingling/numbness (paresthesias - very common)
• Polyuria (diuresis)
• Drowsiness
• Hypokalemia
• GI upset
• Contraindicated in sulfa allergy (sulfonamide derivative)

---

Summary

---

Acute Mountain Sickness (AMS): Symptoms and Detection

What is AMS?

• Murray & Nadel's Respiratory Medicine, p. 3630
• Guyton & Hall Medical Physiology, p. 3785

---

Symptoms

Cardinal (Required) Symptom

• Bitemporal (both sides of the forehead/temples)
• Throbbing in character
• Worse at night, on awakening, or when suddenly standing upright

Associated Symptoms (at least 1 required alongside headache)

Note: Sleep disturbance was previously a formal criterion but was removed from the revised Lake Louise Score after studies showed it was not closely correlated with true AMS.

• Rosen's Emergency Medicine, p. 419
• Murray & Nadel's, p. 3632-3633

Physical Signs (generally few)

• Mildly elevated body temperature
• Crackles on lung auscultation (early)
• Peripheral edema
• Lower oxygen saturation (SpO2) compared to healthy individuals at the same altitude - though AMS can still occur with normal SpO2

---

Time Course

• Murray & Nadel's, p. 3640-3644

---

How to Detect AMS: The Lake Louise Score (LLS)

• Tintinalli's Emergency Medicine, Table 216-2

---

Warning Signs: When AMS is Progressing to Something Worse

1. High-Altitude Cerebral Edema (HACE)

• Ataxia (loss of coordination - cannot walk a straight line)
• Altered mental status (confusion, disorientation, drowsiness)
• These mandate immediate descent - do NOT wait

2. High-Altitude Pulmonary Edema (HAPE)

• Dyspnea at rest (shortness of breath even when not moving)
• Dry cough progressing to productive/frothy cough
• Note: Dyspnea on exertion alone is normal at altitude and does not indicate HAPE
• Rosen's Emergency Medicine, p. 437-439

---

Differential Diagnoses to Rule Out

• Dehydration
• Hypothermia
• Hyponatremia
• Exhaustion
• Acute carbon monoxide poisoning (common in poorly ventilated high-altitude shelters with stoves/generators - especially dangerous as hypoxia worsens CO toxicity)
• Alcohol hangover
• CNS infection (meningitis)

• Murray & Nadel's, p. 3638

---

Key Diagnostic Principle

AMS is a clinical diagnosis. There are no confirmatory laboratory tests. The diagnosis rests entirely on history and symptom scoring in the right setting (recent ascent above ~2,400 m / 8,000 ft). A normal neurologic exam and normal mental status distinguish AMS from the more dangerous HACE.

---

Rabies Prophylaxis Regimens in India

---

Step 1: Wound Category Classification (WHO/India)

---

Step 2: Wound Management (All Categories II & III)

1. Wash wound thoroughly with soap and water for at least 15 minutes
2. Apply povidone-iodine (virucidal) or 70% alcohol to the wound
3. Do NOT suture the wound immediately (increases viral penetration)
4. Give tetanus prophylaxis if indicated
5. Give antibiotics if indicated for secondary infection

---

POST-EXPOSURE PROPHYLAXIS (PEP) - India's Preferred Regimen

Vaccines Available in India

Preferred Route: Intradermal (ID) - India's Standard Since 2004

Updated Thai Red Cross (TRC) / 2-Site ID Regimen (India's standard PEP)

• Total visits: 4 (Days 0, 3, 7, 28)
• Total vaccine used: equivalent to ~1 vial (cost-saving vs IM)
• Site: deltoid region bilaterally; anterolateral thigh in infants

Alternative Route: Intramuscular (IM)

Essen Regimen (1-1-1-1-1) - Standard IM Schedule

• 5 doses over 28 days
• Never in the gluteal area (fat impairs absorption)
• Infants: anterolateral thigh

Zagreb Regimen (2-1-1) - Faster IM Schedule

• Only 3 visits over 21 days - useful for poor compliance situations

India note: The Essen 5-dose IM and the 2-site ID regimen are both government-approved. The ID route is preferred in government facilities due to cost.

---

Rabies Immunoglobulin (RIG) - Category III Only

Types Available in India

How to Administer RIG (India guidelines, updated)

• Infiltrate the ENTIRE dose directly into and around the wound
• If anatomically not feasible (e.g., finger tip fully infiltrated), give remaining volume IM at a site distant from vaccine
• Do NOT inject RIG in the same syringe or same site as the vaccine
• RIG is given only ONCE on Day 0
• If RIG was not given on Day 0, it can be administered up to Day 7 only - after Day 7 it is not beneficial (active immunity is already developing)
• Previously vaccinated persons: RIG is NOT given

---

PRE-EXPOSURE PROPHYLAXIS (PrEP) - India

Who Should Get PrEP?

• Laboratory staff handling rabies virus/infected material
• Clinicians attending human rabies cases
• Veterinarians and animal handlers/catchers
• Wildlife wardens and quarantine officers
• Travelers from rabies-free areas to India
• Children (recommended by Indian Academy of Pediatrics - IAP, on voluntary basis)

PrEP Schedule

• 3 doses total (Days 0, 7, and 21 or 28)
• Provides immunological memory ("priming") - does NOT eliminate need for PEP after exposure, but eliminates need for RIG and reduces vaccine doses

Booster Doses After PrEP

• Goldman-Cecil Medicine; Tintinalli's, Table 158-2

---

RE-EXPOSURE PROPHYLAXIS (Previously Vaccinated)

They Need ONLY:

• Just 2 doses (Days 0 and 3)
• NO RIG - ever, regardless of wound category
• This applies whether the prior vaccination was given IM or ID, and whether or not the person currently has detectable antibodies (anamnestic response is reliable)

If the previously vaccinated person received only a nerve tissue vaccine (NTV) - now banned in India but historically used - they should be treated as unvaccinated and receive full PEP with RIG.

---

Special Situations in India

---

Quick Summary Table

---

Immediate Treatment of Acute MI (Heart Attack) - 59-Year-Old Diabetic Male

---

Step 1: First Few Minutes - At Presentation

Step 2: Immediate Medications (the old "MONA" is now refined)

---

Step 3: Definitive Treatment - Reperfusion

If STEMI (ST-elevation on ECG):

• Primary PCI (angioplasty/stenting) is the gold standard - target: door-to-balloon time under 90 minutes
• If PCI is not available within 120 minutes of diagnosis: fibrinolytic therapy (thrombolysis, e.g., tenecteplase) within 30 minutes of arrival, then transfer for PCI
• In diabetics specifically: STEMI is optimally managed with primary PCI - this is well-established

If NSTEMI/Unstable Angina (no ST elevation):

• Risk-stratify (GRACE/TIMI score)
• High-risk features (ongoing pain, hemodynamic instability, dynamic ECG changes, elevated troponin) → early invasive strategy (catheterization within 24 hours)
• Diabetics with ACS tend to have more severe, diffuse coronary disease - revascularization strategy (PCI vs CABG) is decided based on extent of disease
• Goldman-Cecil Medicine, Ch. 58-59

---

Step 4: Diabetes-Specific Glucose Management

• Target blood glucose: 140-180 mg/dL during the acute MI period (not too tight, not too loose)
• Avoid both hyperglycemia and hypoglycemia - both independently increase mortality risk after MI
• The DIGAMI trial showed intensive insulin-glucose infusion followed by long-term insulin reduced 12-month mortality by 30% in diabetics with MI
• However, the follow-up DIGAMI-2 trial did not show a mortality difference between insulin strategies - the key takeaway is glucose control matters, but the exact method (insulin infusion vs other) is less critical than avoiding extremes
• Continue or initiate statin therapy - diabetics benefit significantly from high-intensity statins post-MI
• SGLT2 inhibitors may have additional cardioprotective benefit and are increasingly used post-MI in diabetics with reduced ejection fraction
• Fuster and Hurst's The Heart, p. 1951

---

Step 5: Watch For Complications (More Common/Severe in Diabetics)

• Heart failure (diabetics develop diabetic cardiomyopathy from chronic microvascular damage)
• Arrhythmias
• Cardiogenic shock
• Silent recurrent ischemia (diabetic neuropathy can blunt pain warning signs)

---

Key Point for This Specific Patient Profile